Loading stock data…
MERCK KGAA I (MRK.DE)
€134.60-0.50 (-0.37%)
Market ClosedLast close Sep 8
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific.
Historical Price
Price (Candle)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
MRK.DE in the Healthcare sector is trading at €134.60 with a market capitalization of $59.3B. Wall Street consensus targets €153.50 (14 analysts), implying a +14.0% move over the next 12 months. The stock is currently 10% below its 52-week high of €148.80, remaining 7.9% above its 200-day moving average. The Whystock Score of 65/100 suggests a balanced risk-reward profile.
Ecosystem Influences
Sell-side targets imply +14.0% upside over 12 months
Long-term trend bullish (price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Quarterly Financials
| Metric (EUR) | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | Q1 2026 |
|---|---|---|---|---|---|
| Total Revenue | €5.28B↑ | €5.25B↓ | €5.32B↑ | €5.25B↑ | €5.13B |
| Gross Profit | €3.15B↑ | €3.03B↓ | €3.21B↑ | €2.96B↓ | €3.06B |
| Operating Income | €1.01B↑ | €892.00M↓ | €1.21B↑ | €547.00M↓ | €943.00M |
| Net Income | €735.00M↑ | €652.00M↓ | €902.00M↑ | €319.00M↓ | €659.00M |
Peer Comparison
JNJUNHPFE
Fundamentals
Merck KGaA operates as a science and technology company in Europe, North America, Latin America, Middle East and Africa, and the Asia Pacific. The Life Science segment offers products, solutions, and services to academic, research and diagnostic labs...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
€59.26B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
23.38
Beta
Defensive asset. Lower volatility than the S&P 500.
0.81
Div Yield
Strong income play. Yield provides a meaningful total return floor.
158.00%
ROE
Average efficiency. Growth may require heavy reinvestment.
8.13%
Volume
Today's trading volume
190,409
Recent News
Merck KGaA shares rise 1.7% after HSBC upgrades stock to Buy
Merck KGaA (NYSE:MRK) shares rose 1. 7% to €141.
Merck KGaA (XTRA:MRK) Stock May Be Below Fair Value Despite Fresh Drug Pipeline Funding
Merck KGaA’s share price has recovered over the past year, yet long term holders are still facing a loss over five years, while the current valuation checks send a mixed message rather than a clear bargain or clear overvaluation. The stock is down about 27.4% over five years, which raises the question of whether the recent rebound is just a partial recovery or a reset to a new trading range. Merck KGaA’s recent role through M Ventures in funding Remepy’s hybrid drug pipeline can support...
Sandoz targets industry patent void with $322m Henlius deal
Sandoz and Henlius will collaborate on up to 10 biosimilars amid opportunity to capitalise on global biosimilar loss-of-exclusivities.
Remepy secures $36m funding for hybrid drug pipeline expansion
The latest round brings the total capital raised by Remepy to $62m.
Merck KGaA (MKGAF) (Q2 2026) Earnings Call Highlights: Robust Growth and Raised Guidance Signal ...
Merck KGaA (MKGAF) delivers 4.1% organic sales growth in Q2 2026, driven by Life Science and Electronics, while raising full-year guidance.